Pipeline

All articles by Pipeline

Analysts reality-check Dupixent’s ‘megabrand’ ambition
Analysts reality-check Dupixent’s ‘megabrand’ ambition
Marc Iskowitz
February 13, 2020
10:25 am

Analysts say the drug’s road to megabrand status may depend on uptake in some rather obscure disease areas.

Pipeline Report 2020: Drugs rising from R&D purgatory, new vaccines set to surge in coming year
Pipeline Report 2020: Drugs rising from R&D purgatory, new vaccines set to surge in coming year
Sony Salzman
December 5, 2019
5:00 am

Several candidates relegated to the R&D graveyard re-emerged from their tombs this year and now headline the pharma developmental slate for 2020.

Analysts: Amarin poised for huge gains if Vascepa trial comes back positive
Analysts: Amarin poised for huge gains if Vascepa trial comes back positive
Alison Kanski
August 6, 2018
7:24 pm

Analysts from Jefferies predicted up to $2 billion in peak sales if Amarin’s seven-year trial data is positive.

Two drugs in the pipeline representing unique marketing challenges
Two drugs in the pipeline representing unique marketing challenges
Sony Salzman
June 5, 2018
6:00 pm

Two touted products in the pipeline reflect three of medical marketing’s most profound modern-era challenges.

Analysts: J&J doesn’t need to worry about Sun Pharma’s prostate cancer drug
Analysts: J&J doesn’t need to worry about Sun Pharma’s prostate cancer drug
Alison Kanski
May 24, 2018
7:50 pm

Sun Pharma’s branded prostate cancer treatment Yonsa just received FDA approval.

Five things for pharma marketers to know: Thursday, February 22, 2018
Five things for pharma marketers to know: Thursday, February 22, 2018
Laura Entis
February 22, 2018
3:42 pm

Novo Nordisk diabetes pill delivers in late-stage trial; Gilead partners with Sangamo on engineered cell therapies; Study finds antidepressants work, though with varying results.

Five things for pharma marketers to know: Wednesday, February 21, 2018
Five things for pharma marketers to know: Wednesday, February 21, 2018
Lauren Evans
February 21, 2018
4:02 pm

AbbVie reports successful elagolix trial; White House touts short-term insurance plans; Mayo Clinic chief to retire.

Flexion’s pivot proves pain-free
Flexion’s pivot proves pain-free
Larry Dobrow
January 24, 2018
12:00 pm

Clayman says the company’s next 18 months are all about Zilretta, with further pipeline construction next up.

Five things for pharma marketers to know: Friday, January 19, 2018
Five things for pharma marketers to know: Friday, January 19, 2018
Virginia Lau
January 19, 2018
3:00 pm

Biogen, UCB reportedly showing interest in Acorda acquisition; Kite Pharma and Pfizer to develop combo lymphoma therapy; hospitals to form generics nonprofit

Five things for pharma marketers to know: Friday, January 5, 2018
Five things for pharma marketers to know: Friday, January 5, 2018
Virginia Lau
January 5, 2018
3:25 pm

Takeda announces deals worth more than $1 billion; biotech and pharma investments reached $10.5 billion in 2017; prescriptions for nerve pain on the rise

  • From Our Partners